#Saudi Arabia #Riyadh #MS Pharma #Biologics Facility

MS Pharma's Revolutionary Biologics Manufacturing Facility

MS Pharma, a leading pharmaceutical multinational, has officially opened the first biologics manufacturing site in the Middle East, strategically located in Riyadh, Saudi Arabia. This groundbreaking facility is not just a production site; it is a catalyst for health advancements in the region, reinforcing partnerships on a global scale.

A Significant Investment for Regional Health

With an investment of 50 million USD, this state-of-the-art plant has received Good Manufacturing Practice (GMP) certification from the Saudi Food and Drug Authority (SFDA). This certification ensures that the facility adheres to the strictest international regulatory standards, paving the way for producing high-quality biologics, such as monoclonal antibodies and complex peptides.

MS Pharma's new facility is equipped with internal bioanalytical laboratories, which streamlines testing processes, reducing reliance on overseas testing services. This local capability accelerates the development and market entry of critical treatments, which is essential to meet the growing health demands of the region.

Aligning with Global Standards

The plant is designed to comply with the regulatory guidelines established by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). This strong regulatory alignment not only increases MS Pharma’s credibility but also positions it as an ideal partner for global pharmaceutical companies seeking localized manufacturing solutions to access the broader Arabian and international markets.

Strategic Impact on the MENA Region

By establishing this facility, MS Pharma significantly boosts its role in the biopharmaceutical landscape across the Middle East and North Africa (MENA) region. According to Ghiath Sukhtian, President of MS Pharma, this launch symbolizes a pivotal moment for the company and the region’s biopharmaceutical sector. He stated, "We are proud to advance a regional biologics platform that aligns with global healthcare demands and supplies high-value complex medications in collaboration with international partners."

Kalle Känd, CEO of MS Pharma, also highlighted that this facility serves as a strategic catalyst for global partnerships, emphasizing the importance of local manufacturing capabilities. He noted, “This site goes beyond production — it will enhance our contributions to national and regional objectives concerning local content, skilled job creation, and technology transfer.”

Experiencing the Local Advantages

Aligned with Saudi Arabia's Vision 2030 plan, the Riyadh plant optimally utilizes industrial incentives and its strategic location to cater to the Kingdom, the MENA region, and export markets in the EU and the U.S. This initiative enhances the accessibility and affordability of critical medications, further solidifying MS Pharma's position as a regional leader in the production of biologics.

By meeting varied market needs, MS Pharma is dedicated to improving health outcomes throughout the region. Established in 1989 in Amman, Jordan, MS Pharma has grown to employ over 2,000 people and has production facilities in Jordan, Algeria, and now Saudi Arabia. Their extensive portfolio includes the development and distribution of generic products, complex injectables, and biosimilars across a wide range of therapeutic areas.

In summary, the inauguration of MS Pharma's biologics manufacturing hub is a monumental step toward enhancing healthcare standards in MENA, ensuring that high-quality medications are readily available to those who need them most. The company stands committed to driving innovation and quality in pharmaceutical manufacturing, partnering with businesses worldwide to bring forth efficient health solutions.